Clinical Trial Update: Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

View source ↗

Summary

Sun Yat-sen University is leading a study evaluating optimized sequential treatment strategies with antibody-drug conjugates in HER2-low expressing breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Low Breast Cancer

Snippet

Sponsor: Sun Yat-sen University | Conditions: Antibody-drug Conjugates, HER2-low Breast Cancer | Status: RECRUITING